Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome.

IF 2.7 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Aging Male Pub Date : 2020-12-01 Epub Date: 2018-11-21 DOI:10.1080/13685538.2018.1541979

Suleyman Sami Cakir, Levent Ozcan, Emre Can Polat, Huseyin Besiroglu, Ramazan Kocaaslan, Alper Ötunctemur, Emin Ozbek

{"title":"Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome.","authors":"Suleyman Sami Cakir, Levent Ozcan, Emre Can Polat, Huseyin Besiroglu, Ramazan Kocaaslan, Alper Ötunctemur, Emin Ozbek","doi":"10.1080/13685538.2018.1541979","DOIUrl":null,"url":null,"abstract":"Objective: To compare the efficacy of statins and ɑ blockers drug therapies for benign prostatic hyperplasia (BPH) in patients with metabolic syndrome (MetS).Materials and method: A total of three hundred patients were randomly distributed into three groups of one hundred patients each. Group 1 received only ɑ-adrenoceptor antagonist (ɑ-blocker, AB) (Tamsulosin), group 2 received only statin (atorvastatin), and group 3 received AB plus statin (Tamsulosin + Atorvastatin). The efficacy measurement was assessed by analyzing the changes from baseline in the total International Prostate Symptom Score (IPSS), disease-specific QoL question score and maximum urinary flow rate at the end of 6 months in each group and between the three groups.Results: Pre-treatment and post-treatment value of triglycerides (TG), high-density lipoprotein (HDL), and prostate volüme (PV) were not significantly different in AB group, while TG and PV were significantly lower in patients taking statin and combined therapy. The significant decrease was demonstrated in maximum urinary flow rate (Qmax) in three groups. However, the most significant decrease was observed in the combination therapy group. IPSS, postvoid residual urine volüme (PVR), and Quality of Life score (QoL) significantly changed in three groups.Conclusion: We recommend of the use of statins in those men with BPH accompanied by MetS in which AB is ineffective alone.","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":"23 5","pages":"538-543"},"PeriodicalIF":2.7000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/13685538.2018.1541979","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Male","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2018.1541979","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/11/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 14

Abstract

Objective: To compare the efficacy of statins and ɑ blockers drug therapies for benign prostatic hyperplasia (BPH) in patients with metabolic syndrome (MetS).

Materials and method: A total of three hundred patients were randomly distributed into three groups of one hundred patients each. Group 1 received only ɑ-adrenoceptor antagonist (ɑ-blocker, AB) (Tamsulosin), group 2 received only statin (atorvastatin), and group 3 received AB plus statin (Tamsulosin + Atorvastatin). The efficacy measurement was assessed by analyzing the changes from baseline in the total International Prostate Symptom Score (IPSS), disease-specific QoL question score and maximum urinary flow rate at the end of 6 months in each group and between the three groups.

Results: Pre-treatment and post-treatment value of triglycerides (TG), high-density lipoprotein (HDL), and prostate volüme (PV) were not significantly different in AB group, while TG and PV were significantly lower in patients taking statin and combined therapy. The significant decrease was demonstrated in maximum urinary flow rate (Q_max) in three groups. However, the most significant decrease was observed in the combination therapy group. IPSS, postvoid residual urine volüme (PVR), and Quality of Life score (QoL) significantly changed in three groups.

Conclusion: We recommend of the use of statins in those men with BPH accompanied by MetS in which AB is ineffective alone.

查看原文本刊更多论文

他汀类药物治疗代谢综合征的良性前列腺增生是有效的。

目的:比较他汀类药物与受体阻滞剂治疗代谢综合征(MetS)患者良性前列腺增生(BPH)的疗效。材料与方法:将300例患者随机分为三组，每组100例。1组仅给予肾上腺素能受体拮抗剂(受体阻滞剂，AB)(坦索洛辛)，2组仅给予他汀类药物(阿托伐他汀)，3组给予AB +他汀类药物(坦索洛辛+阿托伐他汀)。通过分析两组及三组之间6个月时国际前列腺症状评分(IPSS)、疾病特异性生活质量问题评分和最大尿流率与基线的变化来评估疗效。结果:AB组治疗前后甘油三酯(TG)、高密度脂蛋白(HDL)、前列腺体积(PV)值差异无统计学意义，而他汀类药物联合治疗组TG、PV值明显降低。三组患者最大尿流率(Qmax)均显著降低。然而，在联合治疗组观察到最显著的下降。三组患者IPSS、空后残尿量 (PVR)、生活质量评分(QoL)均有显著变化。结论:我们推荐他汀类药物用于BPH合并met的男性患者，单用AB无效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Aging Male 医学-泌尿学与肾脏学

CiteScore

6.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Aging Male , the official journal of the International Society for the Study of the Aging Male, is a multidisciplinary publication covering all aspects of male health throughout the aging process. The Journal is a well-recognized and respected resource for anyone interested in keeping up to date with developments in this field. It is published quarterly in one volume per year. The Journal publishes original peer-reviewed research papers as well as review papers and other appropriate educational material that provide researchers with an integrated perspective on this new, emerging specialty. Areas of interest include, but are not limited to: Diagnosis and treatment of late-onset hypogonadism Metabolic syndrome and related conditions Treatment of erectile dysfunction and related disorders Prostate cancer and benign prostate hyperplasia.